Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOCETUX phase II study of cetuximab + cisplatin + docetaxel in advanced gastric or gastroesophageal junction adenocarcinoma
2006-003838-15Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, cisplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Confirmed response rate. Started Jun 2007; status: completed.
02
Drugs
cetuximabcisplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2006-003838-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003838-15.